Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

2.87 1.77

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.7800000000000002

Максимум

2.89

Ключови измерители
By Trading Economics
Приходи	6.8M -18M
Продажби	9.1M 12M
EPS	-0.15
Марж на печалбата	-153.322
Служители	87
EBITDA	3.9M -20M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+183.69% upside

Дивиденти
By Acuity
Следващи печалби	9.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	25M 432M
Предишно отваряне	1.1
Предишно затваряне	2.87

Настроения в новините

By Acuity

75%

25%

302 / 340 Класиране в Healthcare

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 22:21 ч. UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

13.08.2026 г., 21:32 ч. UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

12.08.2026 г., 19:31 ч. UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

11.08.2026 г., 19:46 ч. UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10.08.2026 г., 23:26 ч. UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7.08.2026 г., 23:16 ч. UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6.08.2026 г., 23:02 ч. UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5.08.2026 г., 22:02 ч. UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31.07.2026 г., 19:56 ч. UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30.07.2026 г., 23:51 ч. UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29.07.2026 г., 23:46 ч. UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28.07.2026 г., 20:07 ч. UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27.07.2026 г., 17:26 ч. UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24.07.2026 г., 17:46 ч. UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22.07.2026 г., 19:26 ч. UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21.07.2026 г., 23:11 ч. UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

183.69% нагоре

12-месечна прогноза

Среден 8 USD 183.69%

Висок 15 USD

Нисък 4 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Настроение

By Acuity

302 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.